News & Activities

Program CD47, provided the CMC service by ProBio to InnobationBio, will further be advanced by the joint venture between Liminatus Pharma LLC and Iris Acquisition Corp - ProBio

A bispecific antibody molecule jointly developed by Buchang Pharmaceutical and REMD Biotherapeutics，partners of ProBio, received IND clearance from NMPA for clinical trial - ProBio

ProBio Licenses Novel Fc Silencing Technology from mAbsolve - ProBio

ProBio Enters Strategic Collaboration with Hibiocy Co. Ltd, the affiliate of Rojukiss International Public Company Limited (KISS) – the leading Thai-based Beauty & Health company, for the development and manufacturing of COVITRAP™ and future new - ProBio

ProBio Signs MOU to Form Strategic Partnership with GeneCraft To Development and Production of New AAV gene therapies - ProBio

ProBio Congratulates Selecxine on FDA Clearance of IND Application for Innovative Antibody Drug Program - ProBio

ProBio and DAAN Bio Therapeutics, Sign a Strategic Cooperation MOU for the Discovery and Development of Novel Drugs - ProBio

ProBio Signs MOU to Form Strategic Partnership with ACT Therapeutics to Development of New CAR-T Cell Therapies - ProBio

ProBio and ProteoNic BV Signed a Strategic Cooperation Based on High Expressing Vector System - ProBio

Athenex Partners with Leading Contract Manufacturer ProBio in the Development of Advanced Cell and Gene Therapies - ProBio

ProBio Signs CDMO Supply Agreement And Forms Strategic Partnership with AffyXell Therapeutics – A Joint Daewong-Avacta Venture- ProBio

National Cancer Center Japan and ProBio Enter Research Collaboration Agreement for a Plasmid & Lentiviral vector CMC development - ProBio

ProBio initiates an Antibody CDMO contract for next-generation CD47 antibody with InnoBation Bio - ProBio

Successful Groundbreaking Ceremony for ProBio to Expand Commercial cGMP Plasmid and Viral Vector Manufacturing Facility in Zhenjiang, China - ProBio

ProBio and AbTis Enter into an Exclusive Worldwide License Agreement for ADC Targeting Claudin 18.2 - ProBio

China’s Largest Commercial GMP Plasmid Manufacturing Facility is Put into Operation, ProBio Expanding Manufacturing Capacity Again - ProBio

ProBio Named a Top 10 Drug Discovery Solution Provider in Asia-Pacific - ProBio

ProBio Passed European Union Qualified Person (QP) Audit Successfully - ProBio

ProBio Congratulates EyeGene for Clinical Trial Approval for mRNA COVID-19 Vaccine in South Korea - ProBio

ProBio and TG ImmunoPharma Enter into Collaboration on Innovative Antibody Drug Project - ProBio